Eton Pharmaceuticals (ETON) Projected to Post Earnings on Tuesday

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) is expected to release its earnings data before the market opens on Tuesday, March 18th. Analysts expect Eton Pharmaceuticals to post earnings of ($0.02) per share and revenue of $10.53 million for the quarter.

Eton Pharmaceuticals Trading Up 1.1 %

ETON traded up $0.16 during trading on Friday, reaching $14.59. 218,799 shares of the company's stock were exchanged, compared to its average volume of 153,598. Eton Pharmaceuticals has a one year low of $3.03 and a one year high of $18.41. The stock has a market capitalization of $380.08 million, a PE ratio of -66.32 and a beta of 1.37. The firm has a fifty day moving average price of $15.22 and a two-hundred day moving average price of $10.87.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ETON. Craig Hallum boosted their target price on shares of Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. B. Riley began coverage on shares of Eton Pharmaceuticals in a research report on Friday, January 10th. They issued a "buy" rating and a $21.00 price target on the stock. Finally, HC Wainwright boosted their price target on shares of Eton Pharmaceuticals from $17.00 to $33.00 and gave the stock a "buy" rating in a research report on Thursday, January 23rd.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.

Remove Ads